Search for: "Fields v. Eli Lilly & Company" Results 21 - 40 of 56
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan Pharmaceuticals ULC… [read post]
5 Jul 2020, 5:43 am by Annsley Merelle Ward
 A number of companies which own existing state of the art technology in this field are making their designs, drawings and instructions freely available and then well-known manufacturing companies are using parts and materials available in the UK supply chain to replicate the designs and increase the available production. [read post]
16 Dec 2013, 1:23 pm
Similarly in Actavis v Eli Lilly [2013] EWCA Civ 517, the Court of Appeal confirmed that the English courts have jurisdiction to hear claims for declarations of non-infringement in relation to foreign designations of European patents where there is no challenge to validity. [read post]
20 Mar 2009, 2:05 am
Eli Lilly & Co., 774 F.2d 830, 835 (7th Cir. 1985); Martinkovic v. [read post]
20 Dec 2023, 5:00 am by Timothy Bonis
Major industry players filed amici briefs on both sides, AbbVie, Bristol Meyers Squibb, and Merck supporting Amgen, and Pfizer, Eli Lilly, Genentech, and AstraZeneca supporting Sanofi. [read post]
26 Apr 2015, 6:14 pm
Complex technology requires complex patentability testsThis Kat is a practitioner in the field of biotech/pharma patents. [read post]
2 Nov 2011, 4:53 am
The Kat had this brilliant idea for what you get when you cross 'Neutrokine-a' with 'genome' Hot off the press and not yet digested, this morning's ruling of the United Kingdom's Supreme Court in Human Genome Sciences Inc. v Eli Lilly and Company [2011] UKSC 51, will be the subject of considerable analysis in the coming days and weeks. [read post]
19 Dec 2019, 9:41 am
  In his reference, the Judge trotted through the English court's and CJEU's case law Article 3(a) - Takeda, Farmitalia, Daiichi, Yeda, Medeva (and its progeny), Actavis v Sanofi, Eli Lilly v HGS, Actavis v Boehringer, - and found that it was clear that something more was required, but what that "something" was was not clear. [read post]
18 Nov 2016, 12:44 am by John Collins
The judge held that the “undue burden” concept in English law (particularly as outlined by Arnold J in Eli Lilly v Janssen in 2014) was not particularly helpful under Australian law. [read post]
20 Feb 2016, 12:30 pm by Rebecca Tushnet
 Peter Yu, The Investment-Related Aspects of Intellectual Property Rights:  Eli Lilly’s $500 million complaint against Canadian gov’t; challenges against plain packaging by tobacco companies. [read post]
7 Dec 2014, 3:29 pm
Among the significant –- but, really, very-well indexed –- number of issues, the decision delves into novelty, inventive step, insufficiency by excessive claim breadth, added matter, and claim construction in light of the influential Actavis v Eli Lilly, another Arnoldian decision that the very same judge clarifies further in this ruling. [read post]
22 Aug 2011, 2:00 am by Stefanie Levine
Eli Lilly and Company, 598 F.3d 1336, 1340 (2010). [read post]
22 Aug 2011, 2:00 am by Stefanie Levine
Eli Lilly and Company, 598 F.3d 1336, 1340 (2010). [read post]
29 Jan 2021, 7:20 am by Nicolas Round (Bristows)
ii) That leads one in turn to consider what the established field which existed was, in which the problem in fact can be located. iii) It is the notional person or team in that established field which is the relevant team making up the person skilled in the art. [read post]
20 May 2012, 1:11 pm
 On the face of it, Plavix's patent expiry may have arguably paved the way for Eli Lilly & Co's and AstraZeneca's own blood-thinning drugs, Effient and Brilinta respectively, to gain more market share but the expiry of the patent does not mean that increasing the market share of their competitor drugs will be easy. [read post]
28 Apr 2013, 8:40 am
Reciting Seager v Copydex and Banks v EMI Songs, the former judge stated that 'where an inventor wanted to sell his idea for money, money is what he got'. [read post]